Page 46 - Haematologica - Vol. 105 n. 6 - June 2020

G. Pavlasova and M. Mraz
21. Levy S, Shoham T. Protein-protein interac- tions in the tetraspanin web. Physiology. 2005;20(4):218-224.
22. Szöllósi J, Horejsí V, Bene L, Angelisová P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol. 1996;157(7):2939-2946.
23. Léveillé C, AL-Daccak R, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol. 1999;29(1):65-74.
24. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80- kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involve- ment of the cytoplasmic regions of CD20. J Biol Chem. 1995;270(38):22632-22638.
25. Manshouri T, Do K, Wang X, et al. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. Blood. 2003;101(7):2507-2513.
26. Schuh E, Berer K, Mulazzani M, et al. Features of human CD3+CD20+ T cells. J Immunol. 2016;197(4):1111-1117.
27. Prevodnik VK, Lavren ak J, Horvat M, Novakovi BJ. The predictive significance of CD20 expression in B-cell lymphomas. Diagn Pathol. 2011;6:33.
28. Olejniczak SH, Stewart CC, Donohue K, Czuczman MS. A quantitative exploration of surface antigen expression in common B- cell malignancies using flow cytometry. Immunol Invest. 2006;35(1):93-114.
29. Fang C, Zhuang Y, Wang L, et al. High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia. Cancer Sci. 2013;104(8):996-1001.
30. Johnson NA, Boyle M, Bashashati A, et al. Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an infe- rior survival. Blood. 2009;113(16):3773- 3780.
31. Horvat M, Kloboves Prevodnik V, Lavrencak J, Jezersek Novakovic B. Predictive signifi- cance of the cut-off value of CD20 expres- sion in patients with B-cell lymphoma. Oncol Rep. 2010;24(4):1101-1107.
32. Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia. Leuk Lymphoma. 2002;43(1):149- 151.
33. Hsi ED, Kopecky KJ, Appelbaum FR, et al. Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. Br J Haematol. 2003;120(6):1017- 1025.
34. Pavlasova G, Borsky M, Svobodova V, et al. Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels. Leukemia. 2018;32(9):2028-2031.
35. Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest. 2010;120(1):214- 222.
36. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol. 2004;16(1):119-129.
37. O’Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics. 1998;48(2): 125-132.
38. Morsy DED, Sanyal R, Zaiss AK, Deo R, Muruve DA, Deans JP. Reduced T-depen- dent humoral immunity in CD20-deficient mice. J Immunol. 2013;191(6):3112-3118.
39. Petrie RJ, Deans JP. Colocalization of the B cell receptor and CD20 followed by activa- tion-dependent dissociation in distinct lipid rafts. J Immunol. 2002;169(6):2886-2891.
40. Li H, Ayer LM, Lytton J, Deans JP. Store- operated cation entry mediated by CD20 in membrane rafts. J Biol Chem. 2003;278 (43):42427-42434.
41. Franke A, Niederfellner GJ, Klein C, Burtscher H. Antibodies against CD20 or B- cell receptor induce similar transcription pat- terns in human lymphoma cell lines. PLoS One. 2011;6(2):e16596.
42. Walshe CA, Beers SA, French RR, et al. Induction of cytosolic calcium flux by CD20 is dependent upon B cell antigen receptor signaling. J Biol Chem. 2008;283(25):16971- 16984.
43. Kheirallah S, Caron P, Gross E, et al. Rituximab inhibits B-cell receptor signaling. Blood. 2010;115(5):985-994.
44. Pavlasova G, Borsky M, Seda V, et al. Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis. Blood. 2016;128(12):1609-1613.
45. Venugopal P, Sivaraman S, Huang XK, Nayini J, Gregory SA, Preisler HD. Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lym- phocytic leukemia. Leuk Res. 2000;24(5): 411-415.
46. Sivaraman S, Venugopal P, Ranganathan R, et al. Effect of interferon-alpha on CD20 antigen expression of B-cell chronic lympho- cytic leukemia. Cytokines Cell Mol Ther. 2000;6(2):81-87.
47. Sivaraman S, Deshpande CG, Ranganathan R, et al. Tumor necrosis factor modulates CD 20 expression on cells from chronic lym- phocytic leukemia: a new role for TNF alpha? Microsc Res Tech. 2000;50(3):251- 257.
48. Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in nor- mal and malignant cells. Eur J Haematol. 2015;94(3):193-205.
49. Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlo- rambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
50. Hörl S, Bánki Z, Huber G, et al. Reduction of complement factor H binding to CLL cells improves the induction of rituximab-medi- ated complement-dependent cytotoxicity. Leukemia. 2013;27(11):2200-2208.
51. Golay J, Lazzari M, Facchinetti V, et al. CD20 levels determine the in vitro suscepti- bility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regu- lation by CD55 and CD59. Blood. 2001;98(12):3383-3389.
52. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss K-D, Bittenbring J. The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lym- phoma treated with CHOP with or without rituximab. Blood. 2011;118(17):4657-4662.
53. Kennedy AD, Beum PV, Solga MD, et al. Rituximab infusion promotes rapid comple- ment depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172(5):3280-3288.
54. Capuano C, Romanelli M, Pighi C, et al. Anti-CD20 Therapy acts via FcγRIIIA to
diminish responsiveness of human natural killer cells. Cancer Res. 2015;75(19):4097- 4108.
55. Racila E, Link BK, Weng W-K, et al. A poly- morphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008;14(20): 6697-6703.
56. Janas E, Priest R, Wilde JI, White JH, Malhotra R. Rituxan (anti-CD20 antibody)- induced translocation of CD20 into lipid rafts is crucial for calcium influx and apopto- sis. Clin Exp Immunol. 2005;139(3):439-446.
57. Tsai P-C, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2012;18(4):1039-1050.
58. Thévenin C, Lucas BP, Kozlow EJ, Kehrl JH. Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. J Biol Chem. 1993;268(8):5949-5956.
59. Himmelmann A, Riva A, Wilson GL, Lucas BP, Thevenin C, Kehrl JH. PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 pro- moter to help confer lineage- and stage-spe- cific expression of CD20 in B lymphocytes. Blood. 1997;90(10):3984-3995.
60. Gstaiger M, Knoepfel L, Georgiev O, Schaffner W, Hovens CM. A B-cell coactiva- tor of octamer-binding transcription factors. Nature. 1995;373(6512):360-362.
61. Nagy M, Chapuis B, Matthes T. Expression of transcription factors Pu.1, Spi-B, Blimp-1, BSAP and oct-2 in normal human plasma cells and in multiple myeloma cells. Br J Haematol. 2002;116(2):429-435.
62. Winiarska M, Nowis D, Bil J, et al. Prenyltransferases regulate CD20 protein levels and influence anti-CD20 monoclonal antibody-mediated activation of comple- ment-dependent cytotoxicity. J Biol Chem. 2012;287(38):31983-31993.
63. Mankaï A, Bordron A, Renaudineau Y, et al. Purine-rich box-1-mediated reduced expres- sion of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. Cancer Res. 2008;68(18):7512-7519.
64. Wojciechowski W, Li H, Marshall S, Dell’Agnola C, Espinoza-Delgado I. Enhanced expression of CD20 in human tumor B cells is controlled through ERK- dependent mechanisms. J Immunol. 2005;174(12):7859-7868.
65. Shimizu R, Kikuchi J, Wada T, Ozawa K, Kano Y, Furukawa Y. HDAC inhibitors aug- ment cytotoxic activity of rituximab by upregulating CD20 expression on lym- phoma cells. Leukemia. 2010;24(10):1760- 1768.
66. Hayashi K, Nagasaki E, Kan S, et al. Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulation. Cancer Sci. 2016;107(5):682-689.
67. Seitz V, Butzhammer P, Hirsch B, et al. Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma. PLoS One. 2011;6(11): e26837.
68. Filip D, Mraz M. The role of MYC in the transformation and aggressiveness of ‘indo- lent’ B-cell malignancies. Leuk Lymphoma. 2020;61(3):510-524.
69. Słabicki M, Lee KS, Jethwa A, et al. Dissection of CD20 regulation in lymphoma using RNAi. Leukemia. 2016;30(12):2409- 2412.
1504
haematologica | 2020; 105(6)